&nbsp;

Jul 2023

Drug

encorafenib

Other Name(s): Braftovi®

Quick Link(s):

Dec 1969

Regimen

ENTR

Cancer Type:

Breast,

Endocrine,

Adrenal,

Neuroendocrine,

Pancreatic Neuroendocrine,

Parathyroid,

Thymoma,

Thyroid,

Gastrointestinal,

Anus,

Colorectal,

Esophagus,

Gastric / Stomach,

Gastrointestinal Stromal Tumours,

Hepatobiliary / Liver / Bile Duct,

Mesothelioma (Peritoneal),

Neuroendocrine (GI),

Pancreas,

Rectal,

Small bowel and appendix,

Genitourinary,

Bladder / Urothelial,

Penile,

Prostate,

Renal cell / Kidney,

Testis,

Gynecologic,

Cervix,

Endometrial,

Germ Cell,

Gestational Trophoblastic Disease,

Ovary,

Uterine Sarcoma,

Vagina,

Vulva,

Head and Neck,

Larynx,

Nasopharynx,

Oral,

Paranasal Sinus,

Pharynx,

Salivary Gland,

Squamous Cell,

Lung,

Neuroendocrine (Lung),

Non-Small Cell,

Small Cell,

Sarcoma,

Desmoid Tumour,

Ewing's,

Ewing's and Soft Tissue,

GIST,

Giant Cell Tumour,

Kaposi's Sarcoma,

Osteogenic / Bone,

Soft Tissue,

Uterine,

Wilm's Tumour,

Skin,

Basal Cell,

Melanoma,

Merkel Cell,

Squamous Cell,

Unknown Primary

Intent: Palliative

Funding:

Exceptional Access Program

entrectinib - Treatment of patients with unresectable locally advanced, or metastatic solid extracranial tumours documented to have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, according to specific criteria

Drugs Used:

entrectinib

Quick Link(s):

Regimen Monograph

Sep 2024

Regimen

LENV+PEMB

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

lenvatinib - In Combination with Pembrolizumab for First-Line Advanced or Metastatic Renal Cell Carcinoma

New Drug Funding Program

Pembrolizumab - In Combination with Lenvatinib for First-Line Advanced or Metastatic Renal Cell Carcinoma

Drugs Used:

lenvatinib,

pembrolizumab

Quick Link(s):

Regimen Monograph

Regimen

TRIFTIPI+BEVA

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

Exceptional Access Program

trifluridine / tipiracil - In combination with bevacizumab for treatment of metastatic colorectal cancer, according to clinical criteria

New Drug Funding Program

Bevacizumab (Biosimilar) - In Combination with Trifluridine and Tipiracil for Previously Treated Metastatic Colorectal Cancer

trifluridine / tipiracil,

Drugs Used:

bevacizumab

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

ZANU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

zanubrutinib - For the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; and for the treatment of adult patients with previously untreated CLL.

Drugs Used:

zanubrutinib

Quick Link(s):

Regimen Monograph

Mar 2024

Drug

selinexor

Other Name(s): Xpovio®

Quick Link(s):

Mar 2024

Drug

zanubrutinib

Other Name(s): Brukinsa®

Quick Link(s):

Mar 2024

Regimen

AZCTGILTVENE

Intent: Curative, Palliative

Funding:

New Drug Funding Program

Azacitidine in combination with Venetoclax (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Exceptional Access Program

venetoclax - Venetoclax in combination with azacitidine - Previously untreated acute myeloid leukemia

Drugs Used:

azaCITIDine,

venetoclax,

gilteritinib (Unfunded)

Quick Link(s):

Regimen Monograph

Regimen

CABO+NIVL; CABO(MNT)

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

cabozantinib – For the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma, in combination with nivolumab, according to clinical criteria

New Drug Funding Program

Nivolumab - In Combination with Cabozantinib for First Line Advanced or Metastatic Renal Cell Carcinoma

Drugs Used:

nivolumab,

cabozantinib (tablet)